Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer To Battle For Antitumor Market In China

This article was originally published in PharmAsia News

Executive Summary

Bayer HealthCare has received China State FDA's approval for Nexavar (sorafenib), its oral drug for treating patients with advanced hepatocellular carcinoma that cannot be removed by surgery. Nexavar, first launched in 2005 in the U.S., represents Bayer's first oncology heavyweight. Industry insiders observe that the drug's speedy launch in China reflects the company's ambition in the antitumor field. According to WHO officials, antitumor drugs in recent years have become the fastest growing sector in China. Several pharmaceutical MNCs are launching their latest antitumor offerings to corner the market. Meanwhile, Simcere Pharmaceutical's acquisition of China-developed cancer drug Endostar (recombinant human endostatin) has opened the door for local firms to contend for a share of the pie. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts